vs
Apellis Pharmaceuticals, Inc.（APLS）与Citi Trends Inc（CTRN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Citi Trends Inc的1.0倍（$199.9M vs $197.1M），Citi Trends Inc净利率更高（-3.5% vs -29.5%，领先26.0%），Citi Trends Inc同比增速更快（10.1% vs -5.9%），Citi Trends Inc自由现金流更多（$767.0K vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Citi Trends Inc是一家美国服装零售连锁品牌，主营折扣服饰商品，目标客群以非裔美国人为主，凭借高性价比的产品策略在美国本土折扣零售市场占据一席之地。
APLS vs CTRN — 直观对比
营收规模更大
APLS
是对方的1.0倍
$197.1M
营收增速更快
CTRN
高出16.0%
-5.9%
净利率更高
CTRN
高出26.0%
-29.5%
自由现金流更多
CTRN
多$15.1M
$-14.3M
两年增速更快
APLS
近两年复合增速
-4.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $197.1M |
| 净利润 | $-59.0M | $-6.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -3.7% |
| 净利率 | -29.5% | -3.5% |
| 营收同比 | -5.9% | 10.1% |
| 净利润同比 | -62.2% | 3.6% |
| 每股收益（稀释后） | $-0.40 | $-0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCTRN
| Q4 25 | $199.9M | $197.1M | ||
| Q3 25 | $458.6M | $190.8M | ||
| Q2 25 | $178.5M | $201.7M | ||
| Q1 25 | $166.8M | $211.2M | ||
| Q4 24 | $212.5M | $179.1M | ||
| Q3 24 | $196.8M | $176.6M | ||
| Q2 24 | $199.7M | $186.3M | ||
| Q1 24 | $172.3M | $215.2M |
净利润APLSCTRN
| Q4 25 | $-59.0M | $-6.9M | ||
| Q3 25 | $215.7M | $3.8M | ||
| Q2 25 | $-42.2M | $871.0K | ||
| Q1 25 | $-92.2M | $-14.2M | ||
| Q4 24 | $-36.4M | $-7.2M | ||
| Q3 24 | $-57.4M | $-18.4M | ||
| Q2 24 | $-37.7M | $-3.4M | ||
| Q1 24 | $-66.4M | $3.6M |
营业利润率APLSCTRN
| Q4 25 | -25.6% | -3.7% | ||
| Q3 25 | 48.7% | 1.8% | ||
| Q2 25 | -18.6% | 0.2% | ||
| Q1 25 | -50.0% | 0.6% | ||
| Q4 24 | -12.3% | -4.9% | ||
| Q3 24 | -24.0% | -14.1% | ||
| Q2 24 | -14.7% | -3.7% | ||
| Q1 24 | -36.0% | 1.8% |
净利率APLSCTRN
| Q4 25 | -29.5% | -3.5% | ||
| Q3 25 | 47.0% | 2.0% | ||
| Q2 25 | -23.6% | 0.4% | ||
| Q1 25 | -55.3% | -6.7% | ||
| Q4 24 | -17.1% | -4.0% | ||
| Q3 24 | -29.2% | -10.4% | ||
| Q2 24 | -18.9% | -1.8% | ||
| Q1 24 | -38.5% | 1.7% |
每股收益（稀释后）APLSCTRN
| Q4 25 | $-0.40 | $-0.86 | ||
| Q3 25 | $1.67 | $0.46 | ||
| Q2 25 | $-0.33 | $0.11 | ||
| Q1 25 | $-0.74 | $-1.70 | ||
| Q4 24 | $-0.30 | $-0.86 | ||
| Q3 24 | $-0.46 | $-2.21 | ||
| Q2 24 | $-0.30 | $-0.42 | ||
| Q1 24 | $-0.54 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $107.8M |
| 总资产 | $1.1B | $464.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCTRN
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSCTRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCTRN
| Q4 25 | $370.1M | $107.8M | ||
| Q3 25 | $401.2M | $113.2M | ||
| Q2 25 | $156.3M | $108.6M | ||
| Q1 25 | $164.2M | $113.2M | ||
| Q4 24 | $228.5M | $130.3M | ||
| Q3 24 | $237.1M | $136.6M | ||
| Q2 24 | $264.3M | $154.8M | ||
| Q1 24 | $266.7M | $157.7M |
总资产APLSCTRN
| Q4 25 | $1.1B | $464.3M | ||
| Q3 25 | $1.1B | $457.4M | ||
| Q2 25 | $821.4M | $437.4M | ||
| Q1 25 | $807.3M | $462.8M | ||
| Q4 24 | $885.1M | $467.1M | ||
| Q3 24 | $901.9M | $506.7M | ||
| Q2 24 | $904.5M | $484.1M | ||
| Q1 24 | $831.9M | $518.7M |
负债/权益比APLSCTRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $8.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $767.0K |
| 自由现金流率自由现金流/营收 | -7.1% | 0.4% |
| 资本支出强度资本支出/营收 | 0.1% | 4.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $11.9M |
8季度趋势，按日历期对齐
经营现金流APLSCTRN
| Q4 25 | $-14.2M | $8.6M | ||
| Q3 25 | $108.5M | $3.9M | ||
| Q2 25 | $4.4M | $-11.0M | ||
| Q1 25 | $-53.4M | $28.5M | ||
| Q4 24 | $19.4M | $-18.4M | ||
| Q3 24 | $34.1M | $5.6M | ||
| Q2 24 | $-8.3M | $-19.6M | ||
| Q1 24 | $-133.0M | $23.3M |
自由现金流APLSCTRN
| Q4 25 | $-14.3M | $767.0K | ||
| Q3 25 | $108.3M | $-1.7M | ||
| Q2 25 | $4.4M | $-13.1M | ||
| Q1 25 | $-53.4M | $26.0M | ||
| Q4 24 | $19.3M | $-20.4M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | $-8.4M | $-21.2M | ||
| Q1 24 | $-133.3M | $20.0M |
自由现金流率APLSCTRN
| Q4 25 | -7.1% | 0.4% | ||
| Q3 25 | 23.6% | -0.9% | ||
| Q2 25 | 2.5% | -6.5% | ||
| Q1 25 | -32.0% | 12.3% | ||
| Q4 24 | 9.1% | -11.4% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | -4.2% | -11.4% | ||
| Q1 24 | -77.3% | 9.3% |
资本支出强度APLSCTRN
| Q4 25 | 0.1% | 4.0% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.2% | 1.5% |
现金转化率APLSCTRN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.01× | ||
| Q2 25 | — | -12.59× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 6.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CTRN
暂无分部数据
